The role of the renin angiotensin system blocking in the management of atrial fibrillation

Acta Cardiologica

Volumn 63, Issue 4, 2008, Pages 457-465

  Soran, Handrean ^a   Ziglam, Hisham ^a   Al Najjar, Merwen ^b   Younis, Naveed ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Atrial fibrillation; Renin agiotensin system blockade

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLYCEROL NITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN;

ADJUVANT THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; PRIMARY PREVENTION; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CORONARY ARTERY BYPASS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 52249086261     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.63.4.2033044     Document Type: Review

References (68)

1. Falk RH. Atrial fibrillation. N Engl J Med 2001; 344: 1067-78.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention (ATRIA) study. JAMA 2001; 285: 2370-5.
3. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, analysis of data from the general practice research database. Heart 2001; 86: 284-8.
4. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med 1995; 98: 476-84.
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-56.
6. Kongings KTS, Kirchof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. High density mapping of electrically induced atrial fibrillation in humans. Circulation. 1994; 89: 1665-80.
7. Frustaci A, Chimenti C, Bellocci F. Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-4.
8. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology, American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conference. Circulation. 2001; 104: 2118-50.
9. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation the Framingham Heart Study, Circulation 1994; 89; 724-30.
10. Tsai CF, Tai CT, Hsieh MH, Lin WS, Yu WC, Ueng KC, Ding YA, Chang MS, Chen SA. Initiation of atrial fibrillation by ectopic beats originating from the superior vena cava: electrophysiological characteristics and results of radiofrequency ablation. Circulation 2000; 102: 67-74.
11. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-66.
12. Kolb C. Nurnberger S, Ndrepepa G, Zrenner B, Schömig A, Schmitt C. Modes of initiation of paroxysmal atrial fibrillation from analysis of spontaneously occurring episodes using a 12-lead Holter monitoring system. Am J Cardiol 2001; 88: 853-7.
13. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 406-13.
14. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-80.
15. Vermes E, Tardif J-C, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Circulation 2003; 107: 2926-31.
16. Maggioni AP Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-57.
17. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86-92.
18. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004: 44: 159-64.
19. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-9.
20. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE. For the Captopril Prevention Project study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
21. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
22. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
23. De Simone A, De Pasquale M, De Matteis C, Canciello M, Manzo M, Sabino L, Alfano F, Di Mauro M, Campana A, De Fabrizio G, Vitale DF, Turco P, Stabile G. Verapamil Plus Antiarrhythmic Drugs Reduce Atrial Fibrillation Recurrences After an Electrical Cardioversion (VEPARAF study), Eur Heart J 2003; 24: 1425-9.
24. Healey JS, Baranchuk A, Crystal E, Garfinkle M, Yusuf S, Connolly SJ. Prevention of Atrial fibrillation with angiotensin-Converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiology 2005; 45: 1832-9.
25. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, Santoro L, Tognoni G. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction the GISSI-3 data. Heart 2001; 86: 527-32.
26. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291: 1720-9.
27. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, de Kam PJ, Lie KL. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995; 1; 355-63.
28. Madrid AH, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-6.
29. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-8.
30. Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, Dai Y, Su L, Ling Z, She Q, Luo K, Woo K, Dong J. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27: 1841-6.
31. Van Noord T, Crijns HJ, van den Berg MP, Van Veldhuisen DJ, Van Gelder IC. Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc Disord 2005; 24: 3-9.
32. Anné W, Willems R, Van der Merwe N, Van de Werf F, Ector H, Heidbüchel H. Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart 2004; 90: 1025-30.
33. Dagres N, Karatasakis G, Panou F, Athanassopoulos G, Maounis T, Tsougos E, Kourea K, Malakos I, Kremastinos DT, Cokkinos DV. Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation. Eur Heart J 2006; 27: 2062-8.
34. Richter B, Derntl M, Marx M, Lercher P, Gössinger HD. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007; 153: 113-9.
35. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, Olgin JE, Wilson MJ, Dimarco JP, Beckman KJ, Dennish G, Naccarelli GV, Ray WA. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004: 1: 669-75.
36. Members of the Sicilian Gambit. The search for novel antiarrhythmic strategies. Eur Heart J 1998; 19: 1178-96.
37. Members of the Sicilian Gambit. New Approaches to Antiarrhythmic Therapy, Part I, Emerging Therapeutic Applications of the Cell Biology of Cardiac Arrhythmias. Circulation 2001; 104: 2865-73.
38. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, Diamond PM, Marra MA, Gersh BJ, Wiebers DO, Petty GW, Seward JB. Left atrial volume important risk marker of incident atrial fibrillation in 1655 older men and women, Mayo Clin Proc 2001; 76: 467-75.
39. Benjamin EJ. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271; 840-4.
40. Kalifa J, Jalife J, Zaitsev AV, Bagwe S, Warren M, Moreno J, Berenfeld O, Nattel S. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003; 108: 668-71.
41. Morillo CA, Klein J, Jones DL, Guiradon CM. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995; 91: 1588-95.
42. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997; 96: 1686-95.
43. Wijffels MC, Kirchhof CJ, Dorland R, Alessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats, Circulation 1995; 92: 1954-68.
44. Shi Y, Ducharme A, Li D, Gaspo R, Nattel S, Tardif JC. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation, Cardiovasc Res. 2001; 52: 217-25.
45. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96: 1180-4.
46. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs atrial remodeling of a different sort. Circulation 1999; 100: 87-95.
47. Tieleman RG, De Langem C, Van Gelder IC, de Kam PJ, Grandjean J, Bel KJ, Wijffels MC, Allessie MA, Crijns HJ. Verapamil reduces tachycardia induced electrical remodeling of the atria. Circulation 1997; 95: 1945-53.
48. Simone A, Stabile G, Vital DF, Turco P, Di Stasio M, Petrazzuoli F, Gasparini M, De Matteis C, Rotunno R, Di Napoli T. Pretreatment with verapamil in patients with pesistant chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999; 34: 810-4.
49. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-77.
50. Willems R, Sipido KR, Holemans P, Ector H, Van de Werf F, Heidbüchel H. Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of AF. J Cardiovasc Electrophysiol 2001; 12: 1387-92.
51. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the AF substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-14.
52. Dodge SM, Beardslee MA, Darrow BJ, Green KG, Beyer EC, Saffitz JE. Effects of angiotensin II on expression of the gap junction channel protein connexin43 in neonatal rat ventricular myocytes. J Am Coll Cardiol. 1998; 32: 800-7.
53. Kass RS, Blair ML. Effects of angiotensin II on membrane current in cardiac Purkinje fibers. J Mol Cell Cardiol. 1981; 13: 797-809.
54. Yu H, Gao J, Wang H, Wymore R, Steinberg S, McKinnon D, Rosen MR, Cohen IS. Effects of the renin-angiotensin system on the current I (to) in epicardial and endocardial ventricular myocytes from the canine heart. Circ Res 2000; 86: 1062-8.
55. Shimoni Y. Hormonal control of cardiac ion channels and transporters. Prog Biophys Mol Biol 1999; 72: 67-108.
56. Sadoshima JI, Izumo S. Mechanical stretch activates multiple signal transduction pathways in cardiac myocytes: potential involvement of an autocrine/paracrine mechanism. EMBO J 1993; 12: 1681-92.
57. Sadoshima JI, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993; 73: 413-23.
58. Sadoshima JI, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression of cardiac myocytes in vitro. Circ Res 1993; 73: 424-38.
59. Sadoshima JI, Jahn L, Takahashi T, ulik TJ, Izumo S. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. J Biol Chem 2001; 267: 10551-60.
60. Ricard P, Danilo P, Cohen IS, Burkhoff D, Rosen MR. A role for the renin-angiotensin system in the evolution of cardiac memory. J Cardiovasc Electrophysiol 1999; 10: 545-51.
61. Schnee JM, Hseuh WA. Review: angiotensin II, adhesion and cardiac fibrosis. Cardiovasc Res 2000; 46: 264-8.
62. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002; 415: 219-26.
63. Goette A, Arndt M, Röcken C, Spiess A, Staack T, Geller C, Huth C, Ansorge S, Klein S, Lendeckel U. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678-81.
64. Goette A, Lendeckel U. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2004; 43: 2363.
65. Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H, Gummert JF, Dhein S. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003; 42: 1785-92.
66. Young M, Funder JW. Aldosterone and the heart. Trends Endocrinol Metab 2000; 11: 224-6.
67. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 2000; 341: 709-17.
68. Kishlay A, Mooses AN, Hee TT, Mohiuddin SM. Metaanalysis: Inhibition of rennin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152: 217-22.